Celltrion to build a $94M+ facility in South Korea — report
Korean biosimilar maker Celltrion will be constructing a new manufacturing facility in South Korea.
A report from Korea Biomedical Review on Tuesday said that Celltrion will spend KRW 126 billion, or $94.4 million, on a new drug product manufacturing facility located at its campus in Songdo, South Korea, just southwest of Seoul.
The report said the new factory is slated to be finished sometime in the beginning of 2026 and will start production in 2027. The facility will also produce “8 million liquid vials annually.” The report did not give details on the size or headcount at the facility. Endpoints News contacted Celltrion for more information but did not get an immediate response.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.